1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. PFIZER LTD.
Pfizer Ltd.
NSE: PFIZER | BSE: 500680

Pfizer Live Share Price Today, Share Analysis and Chart

Mid-range Performer
aboutPfizer Limited is a leading pharmaceutical company in India, operating as a subsidiary of the global biopharmaceutical giant Pfizer Inc. The company focuses on the discovery, development, and manufacturing of healthcare products, primarily in the are... Read More
US FDA Inspections
Ask AI about Pfizer
3821.60182.90(5.03%)

28.42% Fall from 52W High

321.9K
NSE+BSE Volume

High volume+gain today

NSE 03 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Rapid Results
Q2FY27 Quarterly Result Announced for Pfizer Ltd. See details
Loading...
- / 100
- / 100
38.0 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

14

S

9

W

4

O

0

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

14Positive9Negative

Pass in checklist60.9%

045
55
100

PE Valuation Check

Right Now
Undervalued
36.3%
1 Year Forward
Undervalued
53.5%
INSIGHTPfizer is undervalued at both current PE and future earnings estimates.

Pfizer Stock Price Analysis

Day Price Range

5.0% 1 Day return
3821.6 (LTP)
3,633.13,892.9
LowHigh

Week Price Range

3.6% 1 Week return
3821.6 (LTP)
3,613.63,892.9
LowHigh

Month Price Range

-1.0% 1 Month return
3821.6 (LTP)
3,5894,123.9
LowHigh

52 Week Price Range

-26.6% 1 Year return
3821.6 (LTP)
3,5895,339
LowHigh
View full Price History/Seasonality

Pfizer Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Pfizer's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
157.9
AVG. ESTIMATE
181
LOW ESTIMATE
169.6
HIGH ESTIMATE
193.3
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 14.6% in FY27

Consensus Recommendation

4 ANALYST Recommendations
BUY

The consensus recommendation from 4 analysts for Pfizer is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Pfizer Technical Analysis

Pfizer EMA & SMA

Neutral0
4 bullish, 4 bearish
Bullish4
Bearish4
5 Day3690.8
10 Day3721.3
12 Day3734.4
20 Day3795.4
26 Day3847.7
50 Day4040.5
100 Day4279.5
200 Day4508.4

Pfizer Delivery And Volume

Daily Avg. Delivery Volume %
02 Nov, 202667.1%
Week61.5%
Month64.9%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Pfizer Resistance and Support

3656.83
Pivot
First Resistance3700.1
Second Resistance3761.4
Third Resistance3804.7
First Support3595.5
Second Support3552.2
Third Support3490.9
Day RSI34.1
Day MACD-113.3
Day MFI33.2
Day MACD Signal Line-124.1

Pfizer Beta

1 Month0.6
1 Year0.6
3 Month0.6
3 Year0.4

Pfizer Price Change Analysis

↓-1.0%
Over 1 Month
LowHigh
35894123.9
↓-20.8%
Over 3 Months
LowHigh
35895149
↓-18.9%
Over 6 Months
LowHigh
35895149
↓-26.6%
Over 1 Year
LowHigh
35895339
All Technicals →

Pfizer Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Pfizer East India B VPromoter18,186,33439.8 %
Atul LimitedPublic958,9272.1 %
Nippon Life India Trustee LtdDii1,880,8314.1 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Pfizer Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
QUANT MUTUAL FUNDBulkPurchase20 Aug 20264899.97267,864BSE
GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIOBulkSell24 Apr 20264700.01426,066BSE
PRUDENTIAL ICICI MUTUAL FUND A/C DISCOVERY FUNDBulkPurchase24 Apr 20264700400,000BSE
All deals
All insider trades

Pfizer Corporate Actions

Pfizer Dividend history and yield

Pfizer dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Pfizer dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
117 Jul 2026
75FINAL17 Jul 2026Equity Share
209 Jul 2025
130SPECIAL09 Jul 2025Equity Share
309 Jul 2025
35FINAL09 Jul 2025Equity Share
421 Aug 2024
35FINAL21 Aug 2024Equity Share
511 Aug 2023
5SPECIAL11 Aug 2023Equity Share

Pfizer Bonus shares

Pfizer bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
112 Jun 2000
1:128 Jun 2000

Pfizer Board Meetings

Pfizer past and upcoming board meetings.

#Ex-Date
PurposeNotes
103 Nov 2026
Quarterly Results-
228 Jul 2026
Quarterly Results-
312 May 2026
Audited Results & Final Dividend-
409 Feb 2026
Quarterly Results-
512 Nov 2025
Quarterly Results-
All Corporate Actions

Pfizer Research Reports

Pfizer research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
128 Jul 2026ICICI Direct
Target
58154755.1Buy22.29%-19.63%pdf
227 Jul 2026ICICI Securities Limited60004710.7Buy27.37%-18.87%pdf
309 Jul 2026ICICI Securities Limited60004731.4Buy26.81%-19.23%pdf
412 May 2026ICICI Direct57504613.5Buy24.63%-17.16%pdf
509 Feb 2026ICICI Direct
Reco
Target
60304960.8Buy21.55%-22.96%pdf
All Reports of Pfizer

Pfizer Corporate Filings

Pfizer BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
03 Nov 2026
Q2FY27 Quarterly Result Announced for Pfizer Ltd.
Pharmaceuticals company Pfizer announced Q2FY27 results Financial Highlights: Total income: For Q2FY27, Total income was Rs 774.19 crore, growing by 10.91% QoQ from Rs 698.01 crore in Q1FY27 and by 13.15% YoY from Rs 684.19 crore in Q2FY26. For H1FY27, Total income achieved Rs 1,472.20 crore, registering an 8.70% YoY increase from Rs 1,354.41 crore in H1FY26. Revenue from operations: During Q2FY27, Revenue from operations stood at Rs 726.86 crore, shifting upwards by 11.28% QoQ from Rs 653.17 crore in Q1FY27 and up 13.16% YoY from Rs 642.34 crore in Q2FY26. For H1FY27, cumulative Revenue from operations was Rs 1,380.03 crore, marking a 10.81% YoY increase from Rs 1,245.39 crore in H1FY26. Profit Before Tax (PBT): For Q2FY27, PBT reached Rs 422.83 crore, showing a sequential increase of 52.82% QoQ against Rs 276.68 crore in Q1FY27 and an annual increase of 65.58% YoY against Rs 255.37 crore in Q2FY26. For H1FY27, PBT stood at Rs 699.51 crore, rising 35.85% YoY from Rs 514.90 crore in H1FY26. Profit After Tax (PAT): Standalone PAT for Q2FY27 was reported at Rs 313.25 crore, increasing by 53.20% QoQ from Rs 204.47 crore in Q1FY27 and expanding by 65.72% YoY from Rs 189.02 crore in Q2FY26. For H1FY27, PAT reached Rs 517.72 crore, representing a 35.97% YoY growth over Rs 380.77 crore in H1FY26. Earnings Per Share (EPS): Basic and Diluted EPS for Q2FY27 was Rs 68.47, demonstrating a 53.21% QoQ change from Rs 44.69 in Q1FY27 and a 65.71% YoY change from Rs 41.32 in Q2FY26. For H1FY27, EPS stood at Rs 113.17, highlighting a 35.97% YoY improvement over Rs 83.23 in H1FY26. Result PDF
PDF
03 Nov 2026
Pfizer Ltd - 500680 - Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.
Please find enclosed unaudited financial results for the quarter and half year ended September 30, 2026 along with the limited review report.
PDF
26 Oct 2026
Pfizer Ltd - 500680 - Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, November 3, 2026 to consider, approve and take on record the unaudited financial results for the quarter and half year ended September 30, 2026.
PDF
09 Oct 2026
Pfizer Ltd - 500680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find attached Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
PDF
02 Oct 2026
Pfizer Ltd - 500680 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.
PDF
VIEW ALL

Pfizer DocumentsAsk MarketMind AI

Pfizer Earnings Call

Pfizer earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
06 Aug 2020PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
04 Feb 2020Earnings Call Transcript - PfizerLink
view all

Pfizer Annual Reports

Pfizer financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Pfizer - Company Profile

Pfizer Management Structure

Pfizer management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Meenakshi NevatiaExecutive Director,Managing Director,Chief Executive Officer977Mar 26
Amit AgarwalExecutive Director - Finance(Finance),Whole Time Director,Chief Financial Officer294Mar 26
Prajeet NairCompany Secretary,Director(Corporate Services)120Mar 26
Mr. Aninda ShomeDirector(Customer.,Supply Chain.)-Mar 26
Mr. Chaitanya NadkarniDirector(Digital.)-Mar 26
Mr. Chetan SolseLead.(Legal.)-Mar 26
Mr. Prashant MahalingamLead.(Internal Medicine,Hospitals Division)-Mar 26
Dr. Manish PaliwalSenior Director(Regulatory Affairs)-Mar 26
Dr. Pankaj GuptaSenior Director(Medical Affairs)-Mar 26
Mr. Saral GuptaDirector(Commercial,Market Access)-Mar 26
Mr. Sharad GoswamiSenior Director(Policy.,Public Affairs)-Mar 26
Mr. Nilesh PendseLead.(Vaccines)-Mar 26
Ms. Reshma ParidaSenior Director(People Experience)-Mar 26

Pfizer Board of Directors

Pfizer Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Meenakshi NevatiaManaging Director & CEO977.1Mar 26
Amit AgarwalExecutive Director - Finance / WTD / CFO294.38Mar 26
P. RenganExecutive Director / Whole Time Director166.67Mar 26
Prajeet NairCS / Director - Corporate Services120Mar 26
MEENA GANESHIndependent Non Exe. Director26.1Mar 26
Pradip ShahChairman(Non Exe)&Dir(Non-Ind)25.1Mar 26
L KrishnakumarIndependent Non Exe. Director25.1Mar 26
Sonia SinghIndependent Non Exe. Director23.65Mar 26

Pfizer Brands

Brands owned by Pfizer

LOGOBRAND NAME
LC-OD Plus
Erythrocin
Dolonex
Corex DX
LOGOBRAND NAME
Targit
Tritorvis
Tadalift
Viagra
LOGOBRAND NAME
Broncovit
Ferrous Ascorbate + Folic Acid
Neurospecial
Cynomycin
LOGOBRAND NAME
CHAPSTICK CLASSIC SPEARMINT
CHAPSTICK CLASSIC STRAWBERRY
CHAPSTICK LIPSHIELD 365
CHLOROMYCETIN APPLICAPS 250MG 1X50
Website: www.pfizerindia.com

About the company - Business Profile

Pfizer Limited is a leading pharmaceutical company in India, operating as a subsidiary of the global biopharmaceutical giant Pfizer Inc. The company focuses on the discovery, development, and manufacturing of healthcare products, primarily in the areas of vaccines, oncology, internal medicine, and inflammation & immunology. With a history spanning over seven decades in the Indian market, Pfizer Limited maintains a significant presence through its diverse therapeutic portfolio and commitment to patient care.

Key Points

  • Key Facts: Pfizer Limited was incorporated in 1950 and is headquartered in Mumbai, Maharashtra. It is a subsidiary of Pfizer Inc., USA, which indirectly holds a 63.92% stake in the company. The company is listed on both the BSE and NSE.
  • Operations and Resources: As of March 31, 2025, the company reported fixed assets of ₹731 crore and maintained cash and bank balances of ₹2,801 crore. The company operates through a network of distributors, stockists, and healthcare professionals across India.
  • Market and Significance: Pfizer Limited serves a wide range of customers, including patients, healthcare professionals, hospitals, and government institutions. It holds a significant position in the Indian pharmaceutical market, particularly in critical therapy areas like vaccines and oncology.
  • Sustainability and Innovation: The company has implemented an Effluent Treatment Plant Sludge De-Watering System to reduce hazardous waste. In logistics, it has transitioned certain routes from air to ocean to reduce its carbon footprint. Pfizer has committed to reaching net-zero emissions by 2040 through collaboration with its Logistics Service Providers.
  • Business Model: Pfizer Limited's business model is centered on providing science-based healthcare solutions. It excels in navigating complex regulatory environments and maintaining high standards of pharmaceutical marketing practices, recently declaring full adherence to the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024.
  • Revenue and Financials (FY 2024-25):
    • Net Sales: ₹2,128 crore (compared to ₹2,081 crore in FY 2023-24).
    • Profit After Tax (PAT): ₹768 crore.
    • Geographical Revenue: Domestic sales form the vast majority of turnover, with exports contributing 5% to the total turnover, reaching countries including Nepal, Sri Lanka, Bangladesh, Ireland, and the Netherlands.
    • Dividend: For FY 2024-25, the Board recommended a final dividend of ₹35 per share and a special dividend of ₹100 per share to commemorate its 75th year in India.
  • Product Highlights: The company's portfolio includes well-established brands in internal medicine, vaccines, and oncology. Recent focus has been on strengthening its "Power Brands" and expanding its reach in the Indian market.
  • Workforce: As of March 31, 2025, Pfizer Limited employed 1,733 total employees, consisting of 1,563 permanent employees and 170 non-permanent staff. The workforce is comprised of 81% male and 19% female employees.
  • Subsidiaries: The company does not have any subsidiaries, associate companies, or joint ventures as of the latest reporting period.
  • Strategic Initiatives: Current focus includes enhancing digital engagement with healthcare professionals, optimizing the supply chain for sustainability, and driving growth in core therapeutic areas. The company celebrated its 75th year of operations in India in 2025.

References

  1. Annual Report May 2025
  2. Annual Report May 2024

Pfizer FAQ

Pfizer today is trading in the green, up by 5.03% at ₹3,821.6.
Pfizer is currently trading up 5.03% on an intraday basis. In the past week the stock rose 3.65%. Stock has been down 20.78% in the past quarter and fell 26.63% in the past year. You can view this in the share price history/seasonality section.
Pfizer is listed on NSE with the ticker PFIZER and on BSE as 500680. It's currently trading on NSE at a share price of ₹3,821.6 and on BSE with a share price of ₹3,760.5.
The market cap of Pfizer is ₹17,482.94 Cr. as of Nov 03, 2026.
Pfizer announced a FINAL dividend of 750% which equals ₹75 in Jul 17, 2026.The last three ex-dates for Pfizer were Jul 09, 2025, Jul 09, 2025 and Aug 21, 2024. To view the full dividend history of Pfizer click here.
Pfizer has never issued stock splits, but it has issued 1 bonus shares since its BSE/NSE listing. The latest announcement for Pfizer bonus shares was on Jun 12, 2000 at a ratio of 1:1.
Pfizer reported ₹698.01 Cr. in revenue, ₹204.47 Cr. in net profit, and ₹292.4 Cr. in EBITD as of Jul 28, 2026 for Q1 FY26-27.
According to the predictions of 4 analysts, the share price prediction for Pfizer is ₹6,008.5 with an upside of 57%.
The PE ratio of Pfizer is 23.78 as of Nov 03, 2026.
The PB ratio of Pfizer is 3.97 as of Nov 03, 2026.
You can view the latest analyst reports on the Pfizer reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×